GILD News

Latest breaking news and updates for GILD stock.

Track all markets on TradingView

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the compan...

What competitive pressure does Yeytuo® face from other long‑acting HIV‑1 PrEP candidates and biosimilars, and how might its uptake influence Gilead's market share in the HIV prevention space? What pricing and reimbursement assumptions should we model for Yeytuo® in European markets, and how does its cost compare to existing daily/monthly PrEP options? How will the EU approval of twice-yearly Yeytuo® affect Gilead's stock valuation and price momentum?
Approval
about 2 hours ago
Read more businesswire

Gilead Sciences Announces Second Quarter 2025 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations. “This was a very successful second quarter for ...

What is the potential impact on Gilead’s cash flow and R&D budget from the new product launch? Will the diversification of Gileod’s portfolio reduce reliance on any single product’s sales? What guidance is Gilead providing for Q3 earnings and revenue growth?
Earnings
19 days ago
Read more businesswire